Previous Pause Next
Home >> News Center >> Research Frontiers >>
RNAi & MicroRNA
Toronto Scientists Develop Open-source, Web-based App That Tracks Reagent Collections PDF Print E-mail
Monday, 15 August 2011 00:46
Researchers at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, led by Dr Karen Colwill and Marina Olhovsky, have developed an open-source, web-based tool to track both large-scale datasets and individual reagents, allowing for easy access, sharing and management of data across various projects and research groups.
Next Generation: Hundreds of Cell-Analyses at Once PDF Print E-mail
Monday, 15 August 2011 00:39

Like a pinball machine, the tiny stationary levers within this new microfluidics chip, direct cells into compartments just large enough to fit one cell. With 300 compartments per chip (a number that could be easily scaled to 1,000 or more), each cell is washed and then lysed, with its contents channeled to a new compartment where real time quantitative PCR begins, reading out the DNA as it’s amplified.

Marina Biotech Demonstrates In Vivo Knockdown of a microRNA With a CRN-Modified Antagomir PDF Print E-mail
Friday, 12 August 2011 00:09
Marina Biotech, Inc., a leading RNA-based drug discovery and development company, reported in vivo data demonstrating up to 2.5-fold derepression of down-stream targets of a well-established microRNA, miR-122, with a Conformationally Restricted Nucleotide (CRN) modified antagonist
Unique MicroRNA Signature Present in Unstable Carotid Plaque PDF Print E-mail
Monday, 08 August 2011 06:11
A unique micro (mi)RNA signature characterizes atherosclerotic plaque that is prone to rupture and cause stroke, Italian researchers report.

They found that carotid atherosclerotic plaque from stroke patients expressed higher levels of 5 miRNAs than carotid atherosclerotic plaque from asymptomatic patients: miRNA-100, miRNA-127, miRNA-145, miRNA-133a, and miRNA-133b.

New Resource To Unlock The Role Of MicroRNAs PDF Print E-mail
Monday, 08 August 2011 00:09

A new resource to define the roles of microRNAs is announced today in Nature Biotechnology. The resource, called mirKO, gives researchers access to tools to investigate the biological role and significance for human health of these enigmatic genes.

NMD and MicroRNA Expression Profiling of The HPCX1 Locus Reveal MAGEC1 as a Candidate Prostate cancer Predisposition Gene PDF Print E-mail
Friday, 05 August 2011 00:46
Several predisposition loci for hereditary prostate cancer (HPC) have been suggested, including HPCX1 at Xq27-q28, but due to the complex structure of the region, the susceptibility gene has not yet been identified.
Permeon Biologics Announces Discovery of Human Intraphilin(TM) Proteins as a Novel Approach to Develop Intracellular Biologic Drugs PDF Print E-mail
Monday, 01 August 2011 17:20
Permeon Biologics, a biopharmaceutical company pioneering a novel class of intracellular protein biologics, today announced the discovery of an entirely new class of naturally occurring human supercharged proteins called Intraphilins(TM).
Scientist Converts Human Skin Cells Into Functional Brain Cells PDF Print E-mail
Monday, 01 August 2011 00:07
A scientist at the Gladstone Institutes has discovered a novel way to convert human skin cells into brain cells, advancing medicine and human health by offering new hope for regenerative medicine and personalized drug discovery and development.
Pocket Chemistry: DNA Helps Glucose Meters Measure More Than Sugar PDF Print E-mail
Friday, 29 July 2011 00:22
Glucose meters aren't just for diabetics anymore. Thanks to University of Illinois chemists, they can be used as simple, portable, inexpensive meters for a number of target molecules in blood, serum, water or food.
Sistemic Offers miRNA Analytical Services PDF Print E-mail
Monday, 25 July 2011 01:59

Sistemic is offering a range of miRNA analytical services that are designed to provide reliable and cost-effective characterisation and QC tools that are applicable to all cell systems.

La Jolla Institute Opens Major RNAi Center For Identyfing Genetic Triggers Of Disease PDF Print E-mail
Monday, 15 August 2011 00:43
A major Center that will propel scientific efforts to pinpoint the specific genes involved in causing immune diseases, cancer and other diseases will be opened today at the La Jolla Institute for Allergy & Immunology.
Dicer and miRNA in Relation to Clinicopathological Variables in Colorectal Cancer Patients PDF Print E-mail
Friday, 12 August 2011 00:12
Dicer is aberrantly expressed in several types of cancers. Applying real-time PCR, we detected the expression of Dicer mRNA in normal mucosa (n=162), primary colorectal cancer (CRC) (n=162) and liver metastasis (n=37), and analysed the relationship between Dicer expression and clinicopathological features.
New Resource to Unlock the Role of microRNAs PDF Print E-mail
Friday, 12 August 2011 00:04
The first mammalian microRNA knockout resource -- mirKO -- will soon be released. This research toolbox of mutant mouse ES cells, in which individual or clustered groups of microRNA genes have been deleted, will help researchers define the role of microRNAs in health and disease.
Potential New Eye Tumor Treatment Discovered PDF Print E-mail
Monday, 08 August 2011 01:13
New research from a team including several Carnegie scientists demonstrates that a specific small segment of RNA could play a key role in the growth of a type of malignant childhood eye tumor called retinoblastoma. The tumor is associated with mutations of a protein called Rb, or retinoblastoma protein. Dysfunctional Rb is also involved with other types of cancers, including lung, brain, breast and bone.
Characterization of Early Host Responses in Adults With Dengue Disease PDF Print E-mail
Friday, 05 August 2011 00:48
While dengue-elicited early and transient host responses preceding defervescence could shape the disease outcome and reveal mechanisms of the disease pathogenesis, assessment of these responses are difficult as patients rarely seek healthcare during the first days of benign fever and thus data are lacking.
Merck Shuts Down RNAi Research Center in SF PDF Print E-mail
Friday, 05 August 2011 00:15

Merck has decided to close down the RNA interference research facility it obtained through its $1.1 billion acquisition five years ago of San Francisco-based Sirna Therapeutics, the company said late today.

New Preclinical Data Suggests MicroRNA-15 Inhibits Cardiomyogenesis PDF Print E-mail
Monday, 01 August 2011 17:18

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that new preclinical data published in the online edition of Circulation Research suggests that microRNA-15 (miR-15) inhibits cardiomyogenesis,

Alnylam and MIT Collaborators Discover Novel “Core-Shell” Nanoparticles for Systemic Delivery of RNAi Therapeutics PDF Print E-mail
Friday, 29 July 2011 00:41

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, together with collaborators at the Massachusetts Institute of Technology (MIT), announced today the publication of new paper describing discovery of “core-shell” nanoparticles for systemic delivery of RNAi therapeutics.

New Mouse Model for Testing Cancer Drugs PDF Print E-mail
Friday, 29 July 2011 00:19
Only one in twenty cancer drugs makes its way from the laboratory to become an approved pharmaceutical product. The majority of new agents are only shown to be unsuitable in the later phases of clinical development which would explain the exorbitantly high development costs of 500 to 600 million euros per new cancer drug. In order to recognize at an earlier stage which side effects are associated with the use of new cancer drugs, a research group under the guidance of the Goethe University has developed a new mouse model.
RNA-Based Cholesterol Drug Is Readied for Human Tests PDF Print E-mail
Monday, 25 July 2011 00:04

A number of drugs can help lower dangerously high cholesterol, but as many as half a million people worldwide are resistant to existing therapies. Alnylam Pharmaceuticals, a leader in the development of therapies using RNA,

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 4 of 45